focus -WSS

focus

author：fashion 2025-08-31 02:02:52 - browse：76752

Ionis Pharmaceuticals, a California biotech that has spearheaded the development of RNA-targeting medicines, announced on Tuesday that its drug against familial chylomicronemia syndrome, a rare and serious disease that prevents the body from breaking down fats, succeeded in a late-stage clinical trial.

The Phase 3 trial, dubbed Balance, enrolled 66 adults who were randomly divided into three groups and given a monthly injection of placebo or one of two doses of olezarsen, the company’s experimental drug. Treatment with the higher dose of the therapy significantly lowered triglycerides in the blood of those on the drug for six months compared to participants given placebo, though a lower dose did not have this effect. Participants on the high dose didn’t have any instances of painful inflammation of the pancreas, one of the disease’s most serious symptoms, while there were 11 such episodes among those on placebo.

Researchers reported that the treatment was also generally safe, with fewer adverse events among those on olezarsen than among the placebo group.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： European officials brace for rough respiratory virus season

WSS

'Investigate these claims': UFO transparency at center of House hearing

European officials brace for rough respiratory virus season

New oral drug delivery patch is modeled after octopus tentacles

New Alzheimer's drugs heat up race for early detection blood tests

WHO recommends second malaria vaccine

Lawsuit highlights wrinkle for disputes over surprise medical bills

knowledge

focus

hotspot

Alkermes shareholders re

What causes rare myocarditis in young men after Covid vaccines?

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

WHO recommends second malaria vaccine

The high cost of giving birth even with insurance

Former reverend arrested for allegedly killing 8

FDA approval of Sarepta Duchenne genetic therapy gives me hope

UHS says company favors patients whose insurance pays more

George Santos makes 1st court appearance after pleading not guilty to 13 counts

IVG is promising — but it won’t replace IVF quite yet

focus

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Health insurers' Q3 question: how much care are people getting?

Search called off for baby washed away in Pennsylvania flash flood

Biden warns of ‘dark winter’ during final presidental debate

Former reverend arrested for allegedly killing 8

STAT Report: Patient voices and perspectives

knowledge

focus

Wikipedia

leisure time